Alumis Corp (ALMS): Rasio rega marang pendapatan

Tandha merek Alumis Inc (ALMS)

The current P/S multiple reflects the valuation dynamics of Alumis Inc. (ALMS), where 104.10 serves as the base parameter value. The anticipated launch of large-scale Phase 3 trials for psoriasis treatment is already priced in. Growth prospects are tied to the development of precision therapies for immune dysfunction and interest from industry behemoths. Business resilience is supported by precision biologics logistics and raw material diversification.

ALMS Multiplikator P/S Alumis Inc. (29.06.2024 - 13.11.2026)

Rincian analitis perusahaan Alumis Corp (ALMS)

- kuotasi saiki lan rata-rata prakiraan nilai:
Rega bursa alumis.com|ALMS - Bagan rega target
- data kapitalisasi bursa:
Nilai pasar Alumis Corp|ALMS - Nilai Total Perusahaan
- statistik nilai buku emiten:
Nilai Aset Bersih saben Saham Alumis|ALMS - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas alumis.com|ALMS - Gunggung Aset Perusahaan
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Alumis Inc.|ALMS - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Alumis Pharma|ALMS - Utang perusahaan|Rasio utang marang kapitalisasi buku Alumis Corp|ALMS - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Alumis|Indikator likuiditas cepet alumis.com
- data bathi lan kelipatan valuasi:
ALMS - Bathi resik|Prakiraan bathi perusahaan Alumis Inc.|ALMS - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Alumis Inc|ALMS - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Alumis Corp|ALMS - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Alumis|ALMS - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan alumis.com|ALMS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Alumis Inc.
- rincian pendapatan lan dodolan emiten:
ALMS - Dodolan perusahaan|Dodolan mangsa ngarep perusahaan alumis.com|ALMS - Multiplikator P/S|Multiplikator Forward P/S Alumis Corp
Analisis fundamental perusahaan:alumis.com ALMS
Produk seri Alumis Corp

Investors use this multiple to determine the business premium by comparing market capitalization to annual revenue. The index calculation allows for an assessment of the development stage of Alumis Inc. (ALMS), where the full capacity of research centers and contract manufacturing organizations confirms the investment phase, making the price-to-sales ratio analysis a key indicator of future revenue growth expectations.

Karo sapa Alumis Inc. saingan

JAZZ - Rega marang dodolan|Rasio rega marang pendapatan Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Rasio rega marang pendapatan|SRRK - Rasio rega marang pendapatan|Rega marang dodolan Centessa Corp|DYN: Multiplikator P/S|Multiplikator rega marang pendapatan edgewisetx.com EWTX|Kapitalisasi marang pendapatan RAPP|Rega marang dodolan Zevra Therapeutics Inc ZVRA|Multiplikator P/S CTNM|Multiplikator P/S Larimar Corp (LRMR)|Rasio rega marang pendapatan Capricor Therapeutics, Inc. CAPR|entradatx.com - Rasio rega marang pendapatan|PTHS: Kapitalisasi marang pendapatan|MNOV - Multiplikator P/S|Serina (SER) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan BioXcel Therapeutics Corp|PMN (ProMIS Neurosciences Inc.) - Multiplikator P/S|Apimeds (APUS) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan AEON Biopharma (AEON)|Koefisien rega marang pendapatan nlspharma.com|Bionomics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan HUGE|Reata Pharmaceuticals - Multiplikator P/S